Holen Sie sich die Stockscreener-App
56.25
6.15%
3.26
Handel nachbörslich:
54.93
-1.32
-2.35%
Schlusskurs vom Vortag:
$52.99
Offen:
$53.24
24-Stunden-Volumen:
783.91K
Relative Volume:
2.22
Marktkapitalisierung:
$3.31B
Einnahmen:
$91.93M
Nettoeinkommen (Verlust:
$-273.87M
KGV:
-17.15
EPS:
-3.28
Netto-Cashflow:
$-140.47M
1W Leistung:
+13.54%
1M Leistung:
+13.34%
6M Leistung:
+28.54%
1J Leistung:
+108.57%
1-Tages-Spanne:
$52.46
$56.58
1-Wochen-Bereich:
$47.61
$56.58
52-Wochen-Spanne:
$23.83
$56.58
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update - GlobeNewswire
Rhythm Pharma stock soars to all-time high of $55.65 - Investing.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price Up 7.4%Here's Why - MarketBeat
Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024 - The Manila Times
What's Next: Rhythm Pharmaceuticals's Earnings Preview - Benzinga
(RYTM) Investment Analysis - Stock Traders Daily
Assenagon Asset Management S.A. Decreases Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Nisa Investment Advisors LLC Has $3.47 Million Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Needham & Company LLC Reaffirms Buy Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Rhythm Pharmaceuticals, Inc. (RYTM) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - MSN
Rhythm Pharmaceuticals (RYTM) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
Rhythm Pharma, Axovia Therapeutics Launch Joint Research Collaboration for Bardet-Biedl Syndrome - Medical Dialogues
Critical Insights From Rhythm Pharmaceuticals Analyst Ratings: What You Need To Know - Benzinga
HC Wainwright Reiterates "Buy" Rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
RYTMRhythm Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Trend Tracker for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome - GlobeNewswire
Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024 - The Manila Times
Guggenheim Initiates Coverage of Rhythm Pharmaceuticals (RYTM) with Buy Recommendation - MSN
Guggenheim Initiates Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
SG Americas Securities LLC Sells 26,208 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Stake Lowered by Wedge Capital Management L L P NC - MarketBeat
Bank of America Increases Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target to $52.00 - MarketBeat
(RYTM) Technical Data - Stock Traders Daily
Q3 2024 EPS Estimates for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Cut by Analyst - MarketBeat
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire
Rhythm Pharmaceuticals shares stay on H.C. Wainwright’s buy list with focus on niche obesity treatments - Investing.com UK
Rhythm Pharmaceuticals (NASDAQ:RYTM) Given "Buy" Rating at HC Wainwright - MarketBeat
Navigating 5 Analyst Ratings For Rhythm Pharmaceuticals - Benzinga
Squarepoint Ops LLC Lowers Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
AQR Capital Management LLC Acquires 32,831 Shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Boosts Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Down 4% - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Bought by Marshall Wace LLP - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Acquired by Algert Global LLC - MarketBeat
Perceptive Advisors LLC Raises Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Frazier Life Sciences Management L.P. Increases Stock Holdings in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Driehaus Capital Management LLC Raises Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Profund Advisors LLC - MarketBeat
Canada Pension Plan Investment Board Has $17.12 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly? - Simply Wall St
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't Only Catalyst On Deck (NASDAQ:RYTM) - Seeking Alpha
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish - Insider Monkey
Rhythm Pharmaceuticals Inc. [RYTM] Shares Jump Approximately 128.63% Over the Year - Knox Daily
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? - MSN
Algorhythm Gains on Role in Buyside Conference - Baystreet.ca
Rhythm Pharmaceuticals announces voting results By Investing.com - Investing.com Australia
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Rhythm Pharmaceuticals Inc-Aktie (RYTM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | Director |
Sep 17 '24 |
Sale |
52.40 |
31,751 |
1,663,803 |
3,000 |
2.02%
0.47%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):